MTNB Valuation

Matinas BioPharma Holdings Inc

Add to Watchlist

Advanced Chart

2.000

-0.06(-2.913%)1D

Overview
Forecast
Valuation
Earnings

MTNB Relative Valuation

MTNB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MTNB is overvalued; if below, it's undervalued.

Historical Valuation

Matinas BioPharma Holdings Inc (MTNB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.73. The fair price of Matinas BioPharma Holdings Inc (MTNB) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.00

Fair

-1.37

Trailing

Forward

-0.29

EV/EBITDA

Matinas BioPharma Holdings Inc. (MTNB) has a current EV/EBITDA of -0.29. The 5-year average EV/EBITDA is -2.93. The thresholds are as follows: Strongly Undervalued below -8.49, Undervalued between -8.49 and -5.71, Fairly Valued between -0.15 and -5.71, Overvalued between -0.15 and 2.62, and Strongly Overvalued above 2.62. The current Forward EV/EBITDA of -0.29 falls within the Historic Trend Line -Fairly Valued range.

-0.70

EV/EBIT

Matinas BioPharma Holdings Inc. (MTNB) has a current EV/EBIT of -0.70. The 5-year average EV/EBIT is -3.28. The thresholds are as follows: Strongly Undervalued below -8.89, Undervalued between -8.89 and -6.08, Fairly Valued between -0.48 and -6.08, Overvalued between -0.48 and 2.33, and Strongly Overvalued above 2.33. The current Forward EV/EBIT of -0.70 falls within the Historic Trend Line -Fairly Valued range.

0.00

Matinas BioPharma Holdings Inc. (MTNB) has a current PS of 0.00. The 5-year average PS is 102.18. The thresholds are as follows: Strongly Undervalued below -277.08, Undervalued between -277.08 and -87.45, Fairly Valued between 291.80 and -87.45, Overvalued between 291.80 and 481.43, and Strongly Overvalued above 481.43. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.89

P/OCF

Matinas BioPharma Holdings Inc. (MTNB) has a current P/OCF of 0.89. The 5-year average P/OCF is -1.16. The thresholds are as follows: Strongly Undervalued below -18.65, Undervalued between -18.65 and -9.90, Fairly Valued between 7.59 and -9.90, Overvalued between 7.59 and 16.34, and Strongly Overvalued above 16.34. The current Forward P/OCF of 0.89 falls within the Historic Trend Line -Fairly Valued range.

-0.73

P/FCF

Matinas BioPharma Holdings Inc. (MTNB) has a current P/FCF of -0.73. The 5-year average P/FCF is -3.54. The thresholds are as follows: Strongly Undervalued below -10.59, Undervalued between -10.59 and -7.06, Fairly Valued between -0.02 and -7.06, Overvalued between -0.02 and 3.50, and Strongly Overvalued above 3.50. The current Forward P/FCF of -0.73 falls within the Historic Trend Line -Fairly Valued range.

Matinas BioPharma Holdings Inc (MTNB) has a current Price-to-Book (P/B) ratio of 1.37. Compared to its 3-year average P/B ratio of 1.95 , the current P/B ratio is approximately -30.05% higher. Relative to its 5-year average P/B ratio of 2.55, the current P/B ratio is about -46.49% higher. Matinas BioPharma Holdings Inc (MTNB) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -145.97%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -90.43% , the current FCF yield is about -100.00% lower.

1.37

P/B

Median3y

1.95

Median5y

2.55

-113.57

FCF Yield

Median3y

-145.97

Median5y

-90.43

Competitors Valuation Multiple

The average P/S ratio for MTNB's competitors is 0.00, providing a benchmark for relative valuation. Matinas BioPharma Holdings Inc Corp (MTNB) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MTNB.A

Matinas BioPharma Holdings Inc

Kiora Pharmaceuticals Inc

Aprea Therapeutics Inc

Dogwood Therapeutics Inc

Loss

9.90M

Performance Decomposition

Market capitalization of MTNB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MTNB in the past 1 year is driven by Unknown.